 |
|
|
   
|
LONG BEACH, California, March 2, 2006 – Obagi Medical Products,
Inc. (Obagi), announced today that they will present three
clinical posters on a novel Benzoyl Peroxide (BPO) formulation
for the treatment of acne at the 64th annual American
Association of Dermatology (AAD) meeting in San Francisco this
week. Three separate clinical trials demonstrate the unique
properties of a new BPO technology that increases penetration in
the follicle, the site of colonization by the pathogenic
bacteria P. acnes. These results were achieved through the
application of Obagi’s Penetrating Therapeutics™ technologies to
a BPO formulation.
Benzoyl peroxide has shown to be an effective therapy for acne;
however, currently marketed formulations may be limited in their
ability to penetrate down to the base of the hair follicle where
P. Acnes bacteria is most active and problematic in acne skin.
In the first study, in-vitro measures of percutaneous absorption
demonstrated more than 2 to 3 times more penetration than other
formulations with up to 10% BPO. This study compared Obagi’s
BPO formulated at a 6.25% concentration, to commercially
available formulations at 6%, 8% and 10% concentrations.
The second study demonstrated the ability of Obagi’s novel
formulation of BPO solution to have greater in vivo bactericidal
effect throughout a 72 hour period after one single application
as compared to both monotherapy and combination therapy BPO
products. This study measured bactericidal activity (or P.
Acnes bacteria kill rates) during the 72 hours after
application, comparing Obagi’s BPO formulated at 5% versus a
commonly prescribed 5% BPO gel, and a 5% BPO/1% clindamycin
combination product.
In the third study Obagi’s BPO solution demonstrated greater in
vivo bactericidal effectiveness against both a BPO monotherapy
and a BPO combination therapy. This study compared the same
formulations used in the 72 hour study, measuring bactericidal
activity over a 16 day, daily treatment cycle.
“These results validate our ability to use our Penetrating
Therapeutics technology platform to drive greater penetration of
an active agent across the skin barrier, generating excellent
clinical results,” said Steve Carlson, Obagi CEO. “This
technology breakthrough represents a new area of therapeutic
focus in skin care for Obagi.”
The AAD meetings take place March 3rd through March 7th, 2006.
Jose Ramirez, PhD of JR Chemical and Judy Hattendorf, Obagi’s
Senior VP of Product Development, will be available at the
poster exhibits #141, 158 and 159 for review and discussion of
the study results. Additional information may be obtained at
the OMP booths #141, 158 and 159.
About Obagi Medical Products, Inc.
Obagi, a leader in the physician-dispensed skin care channel
develops and commercializes skin health products for the
dermatology, plastic surgery, and related Aesthetic markets.
Using its Penetrating Therapeutics™ technologies, Obagi’s
products are designed to improve penetration of agents across
the skin barrier common and visible skin conditions in adult
skin such as chloasma, melasma, senile lentigines, acne vulgaris
and sun damage. Obagi launched its first skincare system, Obagi
Nu-Derm, in 1988; and in 2004 launched the first and only
prescription strength Vitamin C and hydroquinone system, Obagi-C
Rx. Obagi System products are only available through physicians.
Visit www.obagi.com for information.
|
|
|
|